Manufacturing of bupivacaine multivesicular liposomes
Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.
1. A process for preparing a plurality of batches of bupivacaine encapsulated multivesicular liposomes (MVLs), the process of manufacturing a batch of the plurality of batches comprising:
(a) mixing a first aqueous solution comprising phosphoric acid with a volatile water-immiscible solvent solution to form a water-in-oil first emulsion, wherein the volatile water-immiscible solvent solution comprises 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) (DPPG) or a salt thereof, 1,2-dierucoylphosphatidylcholine (DEPC), tricaprylin and cholesterol, and wherein either the first aqueous solution or the solvent solution comprises bupivacaine;
(b) mixing the water-in-oil first emulsion with a second aqueous solution to form a water-in-oil-in-water second emulsion, wherein the second aqueous solution comprises lysine and at least one osmotic agent;
(c) substantially removing the volatile water-immiscible solvent from the water-in-oil-in-water second emulsion by sparging the water-in-oil-in-water second emulsion to form a first aqueous suspension of bupivacaine encapsulated MVLs having a first volume;
(d) reducing the first volume of the first aqueous suspension of bupivacaine encapsulated multivesicular liposomes by a first microfiltration to provide a second aqueous suspension of bupivacaine encapsulated MVLs having a second volume, wherein the first microfiltration feed flow rate is 200 L/min to 400 L/min;
(e) exchanging the second aqueous suspension medium with a saline solution by diafiltration to provide a third aqueous suspension of bupivacaine encapsulated MVLs having a third volume, wherein the diafiltration feed flow rate is 200 L/min to 350 L/min; and
(f) reducing the third volume of the third aqueous suspension by a second microfiltration to provide a batch of aqueous suspension of bupivacaine encapsulated MVLs having a target concentration of bupivacaine from 12 mg/mL to 17 mg/mL;
manufacturing a plurality of batches according to the steps of (a)-(f);
wherein the plurality of batches are manufactured within a period of six months and each of the batches has a volume of about 100 liters to about 300 liters;
wherein each batch has a cumulative percentage release of bupivacaine from 46% to 71% at a 24-hour time point, measured from two to six aliquots of each batch using a rotator-facilitated in vitro release assay for at least 48 hours, after storage of the aliquots of each batch at 2° C. to 8° C. for about 12 months from batch manufacture date; and
wherein an average rate of change in the cumulative percentage release of bupivacaine at the 24-hour time point is 0.05%/month to 0.5%/month after storage of the aliquots of each batch at 2° C. to 8° C. for about 12 months.
2. The process of claim 1 , wherein the average rate of change in the cumulative percentage release of bupivacaine at the 24-hour time point is 0.08%/month to 0.5%/month.
3. The process of claim 2 , wherein the average rate of change in the cumulative percentage release of bupivacaine at the 24-hour time point is 0.1%/month to 0.4%/month.
4. The process of claim 1 , wherein each batch has a cumulative percentage release of bupivacaine from 60% to 85% at a 48-hour time point, and an average rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is −0.3%/month to 0.33%/month after storage of the aliquots of each batch at 2° C. to 8° C. for about 12 months.
5. The process of claim 4 , wherein the average rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is −0.2%/month to 0.30%/month.
6. The process of claim 5 , wherein the average rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is from −0.18%/month to 0.28%/month.
7. The process of claim 1 , wherein the average rate of change in the cumulative percentage release of bupivacaine is based on three batches, and one batch is manufactured 10 or more days apart from at least one other batch.
8. The process of claim 1 , wherein the average rate of change in the cumulative percentage release of bupivacaine is based on two batches, and one batch is manufactured 10 or more days apart from the other batch.
9. The process of claim 1 , wherein the plurality of batches are manufactured within a period of 3 months.
10. The process of claim 1 , wherein the plurality of batches are manufactured within a period of 30 days.
11. The process of claim 1 , wherein the cumulative percentage release of bupivacaine of each batch is measured as the average of six aliquots from each batch.
12. The process of claim 1 , wherein each aliquot has a cumulative percentage release of bupivacaine from 36% to 81% at the 24-hour time point, and a cumulative percentage release of bupivacaine from 50% to 95% at a 48-hour time point.
13. The process of claim 1 , wherein the mixing in step (a) is performed at a high speed from about 1100 rpm to about 1300 rpm for about 65 minutes to about 75 minutes.
14. The process of claim 1 , wherein the water-in-oil first emulsion has a volume of about 200 L to about 260 L.
15. The process of claim 1 , wherein the mixing in step (b) is performed at a low speed from about 445 rpm to about 680 rpm for about 60 seconds to about 85 seconds.
16. The process of claim 1 , wherein the plurality of batches are manufactured within a period of 3 months, wherein the average rate of change in the cumulative percentage release of bupivacaine is based on three batches, and one batch is manufactured 10 or more days apart from at least one other batch, and wherein the cumulative percentage release of bupivacaine of each batch is measured as the average of six aliquots from each batch.
17. The process of claim 1 , wherein the plurality of batches are manufactured within a period of 30 days, wherein the average rate of change in the cumulative percentage release of bupivacaine is based on two batches, and one batch is manufactured 10 or more days apart from the other batch, and wherein the cumulative percentage release of bupivacaine of each batch is measured as the average of six aliquots from each batch.
18. The process of claim 16 , wherein the first microfiltration feed flow rate comprises a beginning first microfiltration feed flow rate from about 290 L/min to about 350 L/min, and an end first microfiltration feed flow rate from about 250 L/min to about 310 L/min.
19. The process of claim 16 , wherein the diafiltration feed flow rate comprises a first stage diafiltration feed flow rate from about 210 L/min to 350 L/min.
20. The process of claim 17 , wherein the first microfiltration feed flow rate comprises a beginning first microfiltration feed flow rate from about 290 L/min to about 350 L/min, and an end first microfiltration feed flow rate from about 250 L/min to about 310 L/min.
21. The process of claim 17 , wherein the diafiltration feed flow rate comprises a first stage diafiltration feed flow rate from about 210 L/min to 350 L/min.
22. A process for preparing a plurality of batches of bupivacaine encapsulated multivesicular liposomes (MVLs), the process of manufacturing a batch of the plurality of batches comprising:
(a) mixing a first aqueous solution comprising phosphoric acid with a volatile water-immiscible solvent solution to form a water-in-oil first emulsion, wherein the volatile water-immiscible solvent solution comprises 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) (DPPG) or a salt thereof, 1,2-dierucoylphosphatidylcholine (DEPC), tricaprylin and cholesterol, and wherein either the first aqueous solution or the solvent solution comprises bupivacaine;
(b) mixing the water-in-oil first emulsion with a second aqueous solution to form a water-in-oil-in-water second emulsion, wherein the second aqueous solution comprises lysine and at least one osmotic agent;
(c) substantially removing the volatile water-immiscible solvent from the water-in-oil-in-water second emulsion by sparging the water-in-oil-in-water second emulsion to form a first aqueous suspension of bupivacaine encapsulated MVLs having a first volume;
(d) reducing the first volume of the first aqueous suspension of bupivacaine encapsulated multivesicular liposomes by a first microfiltration to provide a second aqueous suspension of bupivacaine encapsulated MVLs having a second volume, wherein the first microfiltration feed flow rate is 200 L/min to 400 L/min;
(e) exchanging the second aqueous suspension medium with a saline solution by diafiltration to provide a third aqueous suspension of bupivacaine encapsulated MVLs having a third volume, wherein the diafiltration feed flow rate is 200 L/min to 350 L/min; and
(f) reducing the third volume of the third aqueous suspension by a second microfiltration to provide a batch of aqueous suspension of bupivacaine encapsulated MVLs having a target concentration of bupivacaine from 12 mg/mL to 17 mg/mL;
manufacturing a plurality of batches according to the steps of (a)-(f);
wherein the plurality of batches are manufactured within a period of six months and the batches each has a volume of about 100 liters to about 300 liters;
wherein each batch has a cumulative percentage release of bupivacaine from 60% to 85% at a 48-hour time point, measured from two to six aliquots of each batch using a rotator-facilitated in vitro release assay for at least 48 hours, after storage of the aliquots of each batch at 2° C. to 8° C. for about 12 months from batch manufacture date; and
wherein an average rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is-0.18%/month to 0.33%/month after storage of the aliquots of each batch at 2° C. to 8° C. for about 12 months.
23. The process of claim 22 , wherein the average rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is −0.15%/month to 0.30%/month.
24. The process of claim 23 , wherein the average rate of change in the cumulative percentage release of bupivacaine at the 48-hour time point is from −0.12%/month to 0.28%/month.
25. The process of claim 22 , wherein the average rate of change in the cumulative percentage release of bupivacaine is based on three batches, and one batch is manufactured 10 or more days apart from at least one other batch.
26. The process of claim 22 , wherein the average rate of change in the cumulative percentage release of bupivacaine is based on two batches, and one batch is manufactured 10 or more days apart from the other batch.
27. The process of claim 22 , wherein the plurality of batches are manufactured within a period of 3 months.
28. The process of claim 22 , wherein the plurality of batches are manufactured within a period of 30 days.
29. The process of claim 22 , wherein the cumulative percentage release of bupivacaine of each batch is measured as the average of six aliquots from each batch.
30. The process of claim 22 , wherein each aliquot has a cumulative percentage release of bupivacaine from 36% to 81% at a 24-hour time point, and a cumulative percentage release of bupivacaine from 50% to 95% at the 48-hour time point.
31. The process of claim 22 , wherein the mixing in step (a) is performed at a high speed from about 1100 rpm to about 1300 rpm for about 65 minutes to about 75 minutes.
32. The process of claim 22 , wherein the water-in-oil first emulsion has a volume of about 200 L to about 260 L.
33. The process of claim 22 , wherein the mixing in step (b) is performed at a low speed from about 445 rpm to about 680 rpm for about 60 seconds to about 85 seconds.
34. The process of claim 22 , wherein the plurality of batches are manufactured within a period of 3 months, wherein the average rate of change in the cumulative percentage release of bupivacaine is based on three batches, and one batch is manufactured 10 or more days apart from at least one other batch, and wherein the cumulative percentage release of bupivacaine of each batch is measured as the average of six aliquots from each batch.
35. The process of claim 34 , wherein the first microfiltration feed flow rate comprises a beginning first microfiltration feed flow rate from about 290 L/min to about 350 L/min, and an end first microfiltration feed flow rate from about 250 L/min to about 310 L/min.
36. The process of claim 34 , wherein the diafiltration feed flow rate comprises a first stage diafiltration feed flow rate from about 210 L/min to 350 L/min.
37. The process of claim 22 , wherein the plurality of batches are manufactured within a period of 30 days, wherein the average rate of change in the cumulative percentage release of bupivacaine is based on two batches, and one batch is manufactured 10 or more days apart from the other batch, and wherein the cumulative percentage release of bupivacaine of each batch is measured as the average of six aliquots from each batch.
38. The process of claim 37 , wherein the first microfiltration feed flow rate comprises a beginning first microfiltration feed flow rate from about 290 L/min to about 350 L/min, and an end first microfiltration feed flow rate from about 250 L/min to about 310 L/min.
39. The process of claim 37 , wherein the diafiltration feed flow rate comprises a first stage diafiltration feed flow rate from about 210 L/min to 350 L/min.